Status:
COMPLETED
Sufentanil as Adjuvant of Balanced Anesthesia
Lead Sponsor:
Kangbuk Samsung Hospital
Conditions:
Anesthesia
Eligibility:
All Genders
19-65 years
Phase:
NA
Brief Summary
The aim of the study was to compare the efficacy and safety between sufentanil and remifentanil as an adjuvant of balanced general anesthesia.
Detailed Description
The investigators hypothesized that sufentanil would reduce postoperative pain than remifentanil without prolonging recovery times in minor laparoscopic surgery when administered equivalent antinocice...
Eligibility Criteria
Inclusion
- Patients aged between 19 and 65 years
- Patients with American Society of Anesthesiologists physical status I or II
- Patients scheduled for elective laparoscopic cholecystectomy under balanced general anesthesia for benign cholecystic diseases
- Patients obtaining written informed consent
Exclusion
- Patients with asthma or hypertension
- Patients with an inability to express their pain accurately
- Patients with an inability to understand the pain scale
- Patients with chronic abdominal pain or chronic pain syndrome
- Patients who required to convert to laparotomy from laparoscopic surgery
- Patients who required to receive incidental lower abdominal procedures owing to adhesion, injury, or other incidental findings at the lower abdominal cavity
- Patients with a history of drug or alcohol abuse
- Pregnant women
Key Trial Info
Start Date :
November 4 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 12 2020
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT03868111
Start Date
November 4 2019
End Date
January 12 2020
Last Update
June 4 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kangbuk Samsung Hospital
Seoul, South Korea, 03181